Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Gassmann

Showing results (71-80 of 102) with videos related to

Pageof 11
Sort By:
Transplantation|June 27, 1995
Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in miceM Zeis, L Uharek, B Glass, et al.
Leukemia|November 1, 1996
High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2L Uharek, M Zeis, B Glass, et al.
British Journal of Haematology|July 1, 1991
High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potentialW Gassmann, L Uharek, A Erbersdobler, et al.
Seminars in Oncology|October 1, 1993
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study GroupW Hiddemann, M Unterhalt, C Pott, et al.
Deutsche Medizinische Wochenschrift (1946)|November 16, 1984
[IgD plasmacytoma]W Gassmann, T Haferlach, K H Engelhardt, et al.
Phytopathology|October 24, 2008
Is Change in Electrical Potential or pH a Hatching Signal for Heterodera glycines?S M Pike, R Heinz, T Walk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapyM Engelhard, P Meusers, G Brittinger, et al.
Haematology and Blood Transfusion|January 1, 1987
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative GroupT Büchner, W Hiddemann, D Urbanitz, et al.
Annals of Hematology|May 1, 1993
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's diseaseN Schmitz, B Glass, P Dreger, et al.
Blood|March 15, 1996
The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridizationT Haferlach, M Winkemann, H Löffler, et al.
Pageof 11

Showing results (71-80 of 102) with videos related to

Sort By:
Pageof 11
Transplantation|June 27, 1995
Allogeneic NK cells as potent antileukemic effector cells after allogeneic bone marrow transplantation in miceM Zeis, L Uharek, B Glass, et al.
Leukemia|November 1, 1996
High lytic activity against human leukemia cells after activation of allogeneic NK cells by IL-12 and IL-2L Uharek, M Zeis, B Glass, et al.
British Journal of Haematology|July 1, 1991
High-dose cytostatic agents in allogeneic bone marrow transplantation: comparison of the engraftment promoting potentialW Gassmann, L Uharek, A Erbersdobler, et al.
Seminars in Oncology|October 1, 1993
Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphomas: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study GroupW Hiddemann, M Unterhalt, C Pott, et al.
Deutsche Medizinische Wochenschrift (1946)|November 16, 1984
[IgD plasmacytoma]W Gassmann, T Haferlach, K H Engelhardt, et al.
Phytopathology|October 24, 2008
Is Change in Electrical Potential or pH a Hatching Signal for Heterodera glycines?S M Pike, R Heinz, T Walk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 1, 1991
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapyM Engelhard, P Meusers, G Brittinger, et al.
Haematology and Blood Transfusion|January 1, 1987
Postinduction and preremission chemotherapy alternatives for adult AML: three multicenter studies of the AML Cooperative GroupT Büchner, W Hiddemann, D Urbanitz, et al.
Annals of Hematology|May 1, 1993
High-dose chemotherapy and hematopoietic stem cell rescue in patients with relapsed Hodgkin's diseaseN Schmitz, B Glass, P Dreger, et al.
Blood|March 15, 1996
The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridizationT Haferlach, M Winkemann, H Löffler, et al.
Pageof 11